INTRODUCTION: In clinical trials, fixed-dose enoxaparin (40 mg once daily) reduces the risk of venous thromboembolism (VTE) in medically-ill patients. However, morbidly obese patients were under-represented in these trials and using fixed-dose enoxaparin in obese patients may be inadequate. We completed a pharmacokinetic study in morbidly obese, medically-ill patients to determine if weight-based dosing of enoxaparin for VTE prophylaxis was feasible, without excessive levels of anticoagulation, as determined by peak anti-Xa levels. MATERIALS AND METHODS: Twenty eight morbidly obese (BMI>or=35 kg/m(2)) patients were enrolled and completed the study protocol. Enoxaparin 0.5 mg/kg was administered once daily subcutaneously and peak anti-Xa levels were measured approximately 4-6 hours after the enoxaparin dose. RESULTS AND CONCLUSIONS: Overall, 46% of patients were female, the average age (+/-SD) was 54 (+/-11) years, and the average weight and BMI were 135.6 kg (+/-25.3) and 48.1 kg/m(2) (+/-11.1), respectively. The average daily dose of enoxaparin was 67 mg (+/-12). The average peak anti-Xa level was 0.25 (SD+/-0.11, range 0.08 to 0.59) units/mL. Peak anti-Xa levels did not significantly correlate with weight or BMI. There were no bleeding events, symptomatic VTE, or significant thrombocytopenia. In morbidly obese, medically-ill patients, use of weight-based enoxaparin dosed at 0.5 mg/kg once daily is feasible and results in peak anti-Xa levels within or near recommended range for thromboprophylaxis, without any evidence of excessive anti-Xa activity. These data suggest that this weight-based regimen may be more effective than standard fixed-dose enoxaparin. Clinical outcome studies are warranted to determine the clinical safety and efficacy of this regimen. (c) 2009 Elsevier Ltd. All rights reserved.
INTRODUCTION: In clinical trials, fixed-dose enoxaparin (40 mg once daily) reduces the risk of venous thromboembolism (VTE) in medically-ill patients. However, morbidly obesepatients were under-represented in these trials and using fixed-dose enoxaparin in obesepatients may be inadequate. We completed a pharmacokinetic study in morbidly obese, medically-ill patients to determine if weight-based dosing of enoxaparin for VTE prophylaxis was feasible, without excessive levels of anticoagulation, as determined by peak anti-Xa levels. MATERIALS AND METHODS: Twenty eight morbidly obese (BMI>or=35 kg/m(2)) patients were enrolled and completed the study protocol. Enoxaparin 0.5 mg/kg was administered once daily subcutaneously and peak anti-Xa levels were measured approximately 4-6 hours after the enoxaparin dose. RESULTS AND CONCLUSIONS: Overall, 46% of patients were female, the average age (+/-SD) was 54 (+/-11) years, and the average weight and BMI were 135.6 kg (+/-25.3) and 48.1 kg/m(2) (+/-11.1), respectively. The average daily dose of enoxaparin was 67 mg (+/-12). The average peak anti-Xa level was 0.25 (SD+/-0.11, range 0.08 to 0.59) units/mL. Peak anti-Xa levels did not significantly correlate with weight or BMI. There were no bleeding events, symptomatic VTE, or significant thrombocytopenia. In morbidly obese, medically-ill patients, use of weight-based enoxaparin dosed at 0.5 mg/kg once daily is feasible and results in peak anti-Xa levels within or near recommended range for thromboprophylaxis, without any evidence of excessive anti-Xa activity. These data suggest that this weight-based regimen may be more effective than standard fixed-dose enoxaparin. Clinical outcome studies are warranted to determine the clinical safety and efficacy of this regimen. (c) 2009 Elsevier Ltd. All rights reserved.
Authors: G P Clagett; F A Anderson; W Geerts; J A Heit; M Knudson; J R Lieberman; G J Merli; H B Wheeler Journal: Chest Date: 1998-11 Impact factor: 9.410
Authors: James W Hainer; Jeffrey S Barrett; Christopher A Assaid; Michael J Fossler; Donna S Cox; Todd Leathers; Philip T Leese Journal: Thromb Haemost Date: 2002-05 Impact factor: 5.249
Authors: Alain Leizorovicz; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Paul T Vaitkus; Samuel Z Goldhaber Journal: Circulation Date: 2004-08-02 Impact factor: 29.690
Authors: Jeroen Diepstraten; Christian M Hackeng; Simone van Kralingen; Jiri Zapletal; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe Journal: Obes Surg Date: 2012-02-01 Impact factor: 4.129
Authors: Christopher J Pannucci; Kory I Fleming; Corinne B Bertolaccini; Ann Marie Prazak; Lyen C Huang; T Bartley Pickron Journal: JAMA Surg Date: 2019-08-01 Impact factor: 14.766
Authors: H Sibai; J T Seki; T Q Wang; N Sakurai; E G Atenafu; K W L Yee; A C Schuh; V Gupta; M D Minden; A D Schimmer; J M Brandwein Journal: Curr Oncol Date: 2016-08-12 Impact factor: 3.677